Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
China Resources Dubl Crne Phrmctl (600062 CH)
Watchlist
26
Analysis
Health Care
•
China
China Resources Double-Crane Pharmaceutical Co., Ltd. develops, manufactures and markets a variety of medical products. The Company's products include anti-influenza, antihypertensives, and antibiotics.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
09 Jul 2015 06:01
Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder
China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...
Kemp Dolliver, CFA
577 Views
Share
bearish
•
Thematic (Sector/Industry)
•
01 Jul 2015 22:01
China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
Kemp Dolliver, CFA
603 Views
Share
bullish
•
Thematic (Sector/Industry)
•
21 Feb 2015 00:02
Opening of E-commerce Channel to Change China's Drug Market
Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...
Kemp Dolliver, CFA
602 Views
Share
bearish
•
China Resources Beverage
•
15 Apr 2025 09:48
China Resources Beverage IPO Lockup- Cornerstones Coming Out of Lockup Ahead of the Large PE Release
China Resources Beverage (2460 HK) raised around US$750m in its Hong Kong IPO in October 2024. The lockup on its cornerstone investors is set to...
Sumeet Singh
Follow
537 Views
Share
bullish
•
China Resources Beverage
•
07 Aug 2024 09:48
China Resources Beverage Pre-IPO - Peer Comparison - Middling
China Resources Beverage is looking to raise US$1bn in its upcoming Hong Kong IPO. We have looked at the company's past performance in our previous...
Sumeet Singh
Follow
535 Views
Share
First
Previous
1
2
3
4
5
6
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x